GT BIOPHARMA, INC. (GTBP) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 2.22M USD | Liabilities, Current |
| Cash and equivalents | 4.96M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $2.22M | $4.96M | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $2.42M | $8.92M | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $2.32M | $6.81M | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $1.32M | $2.53M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $2.31M | $5.23M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $3.64M | $2.37M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $5.90M | $3.95M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $4.66M | $6.42M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $3.76M | $9.25M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $4.60M | $1.95M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $6.63M | $1.08M | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $5.09M | $2.65M | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $4.84M | $2.77M | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $4.08M | $2.04M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $4.94M | $5.67M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $5.03M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $8.61M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $9.50M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $10.26M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $3.92M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $3.28M | $39.50M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $3.63M | $27.55M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $35.09M | $5.30M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $30.69M | $350.00K | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $28.56M | $851.00K | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $21.15M | $5.00K | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $19.71M | $28.00K | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $18.77M | $313.00K | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $16.73M | $264.00K | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $15.52M | $51.00K | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $14.03M | $60.00K | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $13.22M | $1.23M | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $8.95M | $1.10M | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $5.08M | $2.87M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $2.68M | $576.00K | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $2.80M | $2.73M | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $20.13M | $39.00K | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $18.35M | $235.00K | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $18.95M | $19.00K | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | $16.97M | $154.00K | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $15.67M | $355.00K | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $19.70M | $30.00K | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $61.17M | $47.00K | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | $22.31M | $42.00K | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | $21.58M | $125.00K | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $50.51M | $1.42M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $29.83M | $855.00K | (m) | $0.00 | $0.00 | (m) |
| 2014-09-30 | (m) | $11.31M | $664.00K | (m) | $0.00 | $26.00K | (m) |
| 2014-06-30 | (m) | $6.86M | $1.00K | (m) | $5.00K | $26.00K | (m) |
| 2014-03-31 | (m) | $6.68M | $4.00K | (m) | $30.00K | $42.00K | (m) |
| 2013-12-31 | (m) | $6.38M | $43.00K | (m) | $40.00K | $42.00K | (m) |
| 2013-09-30 | (m) | $6.03M | $0.00 | (m) | (m) | $40.00K | (m) |
| 2013-06-30 | (m) | $5.76M | $11.00K | (m) | (m) | $120.00K | (m) |
| 2013-03-31 | (m) | $5.41M | $0.00 | (m) | (m) | $94.00K | (m) |
| 2012-12-31 | (m) | $6.56M | $123.00K | (m) | (m) | $59.00K | (m) |
| 2012-09-30 | (m) | $6.33M | $61.00K | (m) | (m) | $0.00 | (m) |
| 2012-06-30 | (m) | $6.56M | $5.00K | (m) | (m) | $92.00K | (m) |
| 2012-03-31 | (m) | $5.43M | $120.00K | (m) | (m) | $12.00K | (m) |
| 2011-12-31 | (m) | $5.23M | $92.00K | (m) | (m) | $12.00K | (m) |
| 2011-09-30 | (m) | $5.28M | $0.00 | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | $5.80M | $89.00K | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | $1.00K | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $5.65M | $54.00K | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | $181.00K | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $571.00K | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $1.29M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |